. Bender, Arch. Microbiol. 113,49-56 (1977) . The invention relates to DNA fragments having the cyclodextrin glycosyltransferase structural gene, to vectors and microorganisms for expression and to a preparation process for the same. s' T AGA AA T GAA A. 5'. A G GAA ACA 6 3 C T A TT AC TT T. 5. AG GAA ACA 6A AT TIT AGAT AA T G AAA. CGT from Klebsiella pneumoniae (for example, M5 al) is a monomeric polypeptide with a molecular weight of about 69,000 D. This polypeptide is synthesized by the bacterium as a precursor protein with a molecular weight of about 73,000D and, with elimination of a signal peptide of 30 amino acid residues, is released from the cell into the medium.
T C C T T T G T C T TA A

T C C T T T G T C T TAAA T C T A TT ACTT T.
The enzyme synthesis is strictly regulated, in particu lar, it is subject to catabolite repression and to induc tion. This means that the enzyme is synthesized only if, for example, Klebsiella pneumoniae M5al grows on starch, cyclodextrins or maltooligosaccharides. If the bacterium grows on other carbon sources then enzyme synthesis is suppressed or not induced. Since there is no question of using maltooligosaccharides and cyclodex trins, for reasons of cost, satisfactory yields of CGT are obtained, but only by continuous culturing of Klebsiella pneumoniae M5al. Continuous culturing is necessary to limit the addition of starch as the carbon source. Since, by reason of its properties (poor solubility, high viscos ity of the solution), starch is a substrate which is diffi cult to manipulate, considerable problems arise in the fermentation. Another critical factor is the use of CGT from the potentially pathogenic bacterium Klebsiella pneumoniae, especially in the foodstuff sector and in the pharmaceutical sector.
Thus, an object of the present invention is to make available live material with which one or more of the following contributory objects can be achieved: the amount of CGT formed should be as large as possi ble;
the regulation of the enzyme synthesis should be modi fied so that it is easy to carry out, that is to say makes possible fermentation with problem-free carbon sources; and there should be provision of non-pathogenic microor ganisms, in particular, bacteria, which produce CGT, and these microorganisms ought to make the enzyme amenable to use in the foodstuff sector and pharma ceutical sector as well.
The foregoing and related objects are attained by the present invention which provides DNA fragments which embrace the cyclodextrin glycosyltransferase structural gene ("CGT structural gene') as well as of DNA fragments whose single strands are able, at not 2 below 20 C., and in particular at a concentration of 1 M NaCl and a temperature not below 25 C., to hybridize with those of the DNA fragments which embrace the CGT structural gene. The DNA fragments may lack 5 the signal or leader coding regions for their expression.
The invention, more particularly, relates to DNA fragments which are of this type and have about 2,068 basepairs (bp), it being possible to cut, using the restric tion enzyme Mae, these DNA fragments out of DNA 10 structures of microorganisms which produce CGT.
Examples of species and strains of microorganisms of this type have been mentioned above. However, the person skilled in the art can also isolate suitable strains from soil samples.
The invention furthermore relates to: expression vectors which embrace the DNA fragments; tac promoter plasmids such as pKK223-3 and pF118u;
Lambda-pil promoter plasmids such as pFL-Lambda; and trp promoter plasmids such as pdR720 Recombination of the resulting DNA fragments, which are about 5,400 base-pairs in length, with the cleaved vector can be effected by mixing the fragments and incubating the solution with a suitable DNA ligase, preferably with the DNA ligase from the phage T4 (E.C.6.5.1.1.). The ligation is preferably carried out in the presence of ATP, of a sulfhydryl compound and magnesium ions. So-called competent strains, which have the ability to take up DNA, are transformed in a known manner with the recombinant DNA which has been obtained.
For the present invention, one could employ as trans formable strains, the strains which are known for this purpose. These are, in particular, strains of E. coli, Kleb siella pneumoniae, Bacillus subtilis and Saccharomyces cerevisiae. Use is made in this first transformation step of strains of E. coli, such as, HB101 (DSM 1452; J. Mol. Biol, 41, (1966) 459-472 In order, after the first transformation step, in the process according to the invention, to find those cells which contain the vector carrying the gene for CGT, one may culture the transformed cells on a minimal medium which contains starch as a carbon source, the necessary salts and supplements, an antibiotic for selec tion of the vector, and amylopectin azure as indicator for starch degradation. The cells which contain the vector carrying the gene for CGT form a colorless degradation zone and are isolated.
For a second recombination step in the process ac cording to the invention, it is possible in stages (c) and (d) to obtain the plasmid DNA from the isolated cells by known methods, and to cut out, with a restriction endonuclease, DNA fragments which embrace the CGT structural gene. A preferred restriction enzyme is Mae (E.C.3.1.23. -), with which partial cleavage is carried out at, for example, about 45 C. The resulting fragments of the plasmid DNA containing the gene for CGT are fractionated by, for example, gel electropho resis. If cutting has been carried out with the restriction endonuclease Mae, then a fragment which has a length of about 2,068 base-pairs and which carries the struc tural gene for CGT, but not the signal structures for its expression, is isolated. The 5' protruding ends of the fragment can be filled in with deoxy-ATP and deoxy TTP by incubation with a suitable DNA polymerase so that blunt ends are produced. The Klenow fragment of DNA polymerase I (E.C.2.7.7.7) is preferably used. In another embodiment of the claimed process, how ever, it is also possible in stage (d) to linearize, with a suitable restriction endonuclease, the vector obtained in the first transformation step, and then to incubate it with an exonuclease, for example with Ba131, until there is produced, by stepwise elimination of nucleotides from the ends, a fragment which contains the gene for CGT but preferably not its signal structures. Protruding ends of the fragment can be filled in with deoxynucleotides using a DNA polymerase so that blunt ends are pro duced.
It is possible for the second recombination step in the process according to the invention, namely stage (e), to use so-called expression vectors which contain readily controllable regulatory sequences and effect high ex pression of the recombined gene. It is possible, for ex ample, to use for the transformation of strains of E. coli and Klebsiella pneumoniae tac promoter plasmids such as pKK223-2 (commercially available) and p) F118u; pJF118u corresponds to PKK223-3 with the exceptions that a 0.546 kb BamHI-Xmal II fragment has been de leted and a 1.26 kb fragment with the lactose repressor gene (LacI9) has been inserted. However, it is also pos sible to use other plasmids, for example, Lambda-pl promoter plasmids such as pPL-Lambda (commercially available), and trp promoter plasmids such as ploR720 (commercially available).
The vector DNA is cleaved with a suitable restriction endonuclease. The restriction endonuclease is then inac tivated. Protruding ends can be filled in with deoxynu cleotides using a suitable DNA polymerase, or can be cleaved off, so that blunt ends are produced. It is possi ble and preferable to use for this purpose the Klenow fragment of DNA polymerase I or the DNA polymer ase of the phage T4.
Recombination of the DNA fragment, which em braces the CGT structural gene with the vector DNA, can be achieved by mixing the fragments and incubating the solution with a suitable DNA ligase, preferably with DNA ligase from the phage T4 (E.C.6.5.1.1.). Ligation is advantageously carried out in the presence of ATP, of a sulfhydryl compound and magnesium ions.
It is possible in stage (f) of the process according to the invention to transform, in a known manner, the resulting recombinant DNA into so-called competent strains which have the ability to take up DNA. In this second transformation step in the process, the selection of the transformable cells is based on other desired properties of these cells, such as, for example, properties of growth, of pathogenicity and of the ability to export proteins. Strains of E. coli, such as, HB101 and JM 105 (commercially available), and Klebsiella pneumoniae, such as, UN1290 (J. Bacteriol. 136, (1978) 253-266) are preferably used. However, it is also possible to use transformable cells of other strains such as, for example, of Saccharomyces cerevisiae and Bacillus subtilis.
After the transformation it is possible to culture those cells which contain plasmids on a nutrient medium which contains an antibiotic. Specifically, one could set up parallel cultures of those cells which contain a plas mid, on the one hand, on a minimal medium which contains glucose as a carbon source, the necessary salts and supplements, an antibiotic for selection of the vec tor, and amylopectin azure as indicator, for starch deg radation. On the other hand, on the same minimal me dium also contains, in addition, an inducer, for example, isopropyl S-D-thiogalactoside, in the case of the vector pKK223-3. Those cells which form a colorless degrada 5,395,927 5 tion zone with the inducer, and thus are obviously under the control of the promoter, are isolated. They have the structural gene for CGT, which is under the control of the expression promoter. This is the tac pro moter in the case of the vector pKK223-3.
In stages (d) and (e) of the process according to the invention, it is advantageous for the second recombina tion step to use the restriction endonuclease Mael for the partial cleavage of the plasmid DNA resulting after the first transformation. This is because the latter re striction enzyme effects cleavage at advantageous sites on the DNA, namely between the ribosome binding site and the site where translation commences, on the one hand, and downstream of the termination signals for transcription and translation of the DNA sequence con taining the gene for CGT on the other hand.
It is emphasized once more that the invention em braces not only the DNA fragments which embrace the CGT structural gene, and can be obtained by the pro cess according to the invention, but also DNA frag ments whose single strands can hybridize with those of the DNA fragments having the CGT structural gene. "Hybridizable' DNA fragments of this type can result from, for example, modification of the DNA fragments which embrace the CGT structural gene. Extension of the invention to include these "hybridizable' DNA fragments also takes into account the fact that the struc tural genes of the microorganisms which produce CGT (FIG. 1) and an example. It is to be understood that the drawing and example are to be used for the purpose of illustration only, and not as a defini tion of the limits of the invention.
EXAMPLE
The following process steps are used to prepare from the entire DNA of the strain Klebsiella pneumoniae M5al, which carries the gene for cyclodextrin glycosyl transferase, new strains of high cyclodextrin glycosyl transferase productivity:
(1) Isolation of the entire DNA from Klebsiella pneu moniae M5al which contains the genetic information for cyclodextrin glycosyltransferase.
The strain Klebsiella pneumoniae M5al is cultured to the end of the exponential phase in 200 ml of nutrient broth which contains 1% tryptone, 0.5% yeast extract and 1% NaCl at 37° C. After harvesting, the cells are taken up in 2.5 ml of TES buffer (50 mM Tris/HCl pH 7.5; 50 mM. NaCl; 5 mM EDTA), which contains su crose and 5 mg Lysozyme, and incubated at 37 C. for 10 minutes. After addition of 2.5 ml of lysis solution (10 mM Tris/HCl pH 7.5; 1 mM EDTA; 0.1% TRITON X100, which is Polyoxyethylene (9-10) p-t-octylphenol, proteinase K is added to the mixture to a final concen tration of 0.1 mg/ml, and the mixture is incubated at 37 C. for 30 minutes. The DNA is isolated from the lysate by cesium chloride density gradient centrifugation and 10 15 20 6 dialysis against buffer (10 mM Tris/HCl pH 8.0; 1 mM EDTA).
(2) Isolation of the vector DNA. DNA of the plasmid p3R322, which carries ampicil lin and tetracycline genes as markers, is used for cloning the gene for cyclodextrin glycosyltransferase. It is iso lated in the following manner: An E. coli strain which contains the plasmid pBR322 is cultured to the end of the exponential growth phase in 0.5 ml of nutrient broth as in (1) The solution of the fragments of the entire DNA of Klebsiella pneumoniae M5al which have thus been ob tained is mixed with the solution of the cleaved pBR322 vector DNA and after addition of ATP, dithiothreitol and magnesium chloride, the mixture is incubated with the DNA ligase of the phage T4 at 17 C. for 16 hours. The resulting solution contains the recombinant DNA.
(4) Genetic transformation of E. coli bacteria with recombinant DNA which contains the genetic informa tion for cyclodextrin glycosyltransferase.
The E. coli strain HB101 is cultured to the end of the exponential phase by shaking in 20 ml of nutrient broth as in (1) (1) and shaken at 37° C. for 45 minutes. The cells are then plated out in portions on agar plates which contain 7.1 g of Na2HPO4, 13.6 g of KH2PO4, 15 mg of CaCl2, 0.25g of MgSO4, 1.6 g of (NH4)2SO4, 5 mg of thiamine, 40 mg of proline, 40 mg of leucine, 20 mg of tetracy cline, 5g of starch, 5g of amylopectin azure and 15 g of agar per liter. The plates are incubated at 37° C. After incubation for 3 days, colonies appear on the plates, some of which are surrounded by colorless zones on the plates which are otherwise deep blue. The latter colo nies are removed, purified and isolated. Each of the colonies thus obtained is able to degrade starch and is, at the same time, tetracycline-resistant. Thus, its proper ties differ from those of the strain used as host organism. This means that the isolated cells contain the plasmid
